Compare RVSB & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | INO |
|---|---|---|
| Founded | 1923 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 116.1M |
| IPO Year | 1993 | 1998 |
| Metric | RVSB | INO |
|---|---|---|
| Price | $5.21 | $1.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $9.00 |
| AVG Volume (30 Days) | 48.8K | ★ 2.0M |
| Earning Date | 01-26-2026 | 11-10-2025 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | ★ 361.12 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $52,756,000.00 | $182,337.00 |
| Revenue This Year | $10.25 | N/A |
| Revenue Next Year | $11.23 | $23,060.18 |
| P/E Ratio | $23.64 | ★ N/A |
| Revenue Growth | ★ 15.20 | N/A |
| 52 Week Low | $4.74 | $1.30 |
| 52 Week High | $6.59 | $2.98 |
| Indicator | RVSB | INO |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 35.49 |
| Support Level | $4.95 | $1.50 |
| Resistance Level | $5.13 | $1.70 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 90.14 | 8.89 |
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.